Fig. 2

CCDC50-S is upregulated in ccRCC tissues, cell lines, and is associated with poor clinicopathological features. a Schematic representation of CCDC50 pre-mRNA and two alternatively spliced mRNA isoforms. Exon 6 (528 bp) is spliced-out in CCDC50-S and spliced-in in CCDC50-FL. b Expression of CCDC50-S and CCDC50-FL mRNA in 12 pairs ccRCC (T) and adjacent noncancerous tissues (N) by RT-PCR. GAPDH was used as the internal control. c Expression of CCDC50-S and CCDC50-FL mRNA in normal human kidney 2 (HK2) cell line and four renal cancer cell lines (ACHN, OS-RC-2, 786-O, A498) by RT-PCR. GAPDH was used as the internal control. d Subcellular localization of CCDC50 protein isoforms in OS-RC-2 cells. Blue fluorescence for DAPI and red fluorescence for CCDC50 isoforms. e The expression of CCDC50-S and CCDC50-FL in 12 pairs ccRCC and normal tissues was determined by Fluorescence in Situ Hybridization (FISH). Representative images of 2 pairs tissues are shown. Blue fluorescence for DAPI, green fluorescence for CCDC50-S and red fluorescence for CCDC50-FL. f The association between CCDC50 isoforms mRNA expression and (a) tissue types, (b) ccRCC T stage and (c) ccRCC Fuhrman Grade were analyzed. Quantitative data are presented as the mean ± SD